Q1 2022

Filed May 13, 2022 · 10-Q · 43 days after period end · 0001493152-22-013332

Q1 2022 · 10-Q

Revenue—

Net Income

-$4.52M

N/M vs Q1 2021

EPS, diluted—

Operating Income-$4,795,845N/M

Operating Cash Flow-$4,548,941N/M

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	—	—	$9.60M	$10.69M
Net Income	-$4.52M	-$3.25M	-$1.78M	-$1.86M
EPS Diluted	—	-$0.20	-$0.60	-$1.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR